

## **Neuropsychological assessment in initial clinical stages of** Parkinson disease

## Mattia Siciliano<sup>1</sup>, R. De Micco<sup>1</sup>, M. De Stefano<sup>1</sup>, C. Baiano<sup>1</sup>, L. Marcuccio<sup>1</sup>, A. De Mase<sup>1</sup>, C. Passaniti<sup>1</sup>, L. Trojano<sup>2,3</sup>, G. Tedeschi<sup>1</sup>, A. Tessitore<sup>1</sup>

Department of Medical, Surgical, Neurological, Metabolic and Aging Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy. <sup>2</sup> Department of Psychology, University of Campania "Luigi Vanvitelli", Naples, Italy.

<sup>3</sup> Salvatore Maugeri Foundation, Scientific Institute of Telese, Telese Terme (BN), Italy

**OBJECTIVE**: To compare cognitive performances in newly diagnosed patients with Parkinson's disease (PD) at Hoehn and Yahr (HY) stage I or stage II at their first medical evaluation.

**METHODS**: Forty de novo PD patients at HY stage I and 40 patients at HY stage II completed a standardized neuropsychological battery. A multivariate analysis of covariance was used to compare cognitive performance between HY groups. Odds ratios (ORs) were employed to explore the risk of cognitive impairment between HY stages. The prevalence of mild cognitive impairment (MCI) was estimated for patients in HY stage I and II. Finally, we also performed a one-way MANOVA to search for any significant neuropsychological difference between PIGDdominant and TD groups.

Table 1. Demographic and clinical characteristics of the patients in Hoehn & Yahr stage I vs. stage II; data are reported as mean standard deviation or as counts (and



**Table 3.** Relationship between the HY stages and risk of cognitive
 impairment – HY stage I and HY stage II.

| HY stage I | HY stage II | OR | р | [95% CI |  |
|------------|-------------|----|---|---------|--|
| N (%)      | N (%)       |    |   |         |  |

**RESULTS**: Demographic and clinical characteristics are reported in Table 1. Patients at HY stage I obtained better scores on neuropsychological tests than patients at HY stage II (Wilks' lambda = .562, F(16, 61) = 2.968, p = .001,  $\eta^2 = .438$ ). Univariate analysis of covariance revealed significant differences between HY stages on Rey's auditory verbal learning test -immediate recall, 10 points Clock Drawing Test, and Rey-Osterrieth Complex Figure Test –copy (Table 2). Odds Ratios (Ors) of having cognitive impairment were greater for HY stage II than stage I group (Table 3). PD-MCI occurred in 7.5% of patients in HY stage I, and in 42.5% of patients in HY stage II. ORs for MCI are 8.22 (95% CI [2.162, 31.271]) times greater for patients at HY stage II than for those at stage I. As for the comparison between PIGD-dominant and TD groups, we did not observe any differences for the main demographic and clinical variables. Oneway MANOVA testing for cognitive differences between these two groups did not show any significant difference, Wilks' lambda = .721, F(15, 52) = 1.342, p = .212.

| Age at onset                                       | 61.03 ± 8.6                                       | 63.57 ±  | 7.35                   | 2.010                      | .160                       |   | g memory               |                        |        |        |                         |
|--|---|--|------------------------|----------------------------|----------------------------|---|------------------------|------------------------|--------|--------|-------------------------|
| Education, years                                   | 11.10 ± 3.7                                       | 77 9.83 ±  | 4.61                   | 1.828                      | .180                       | > - 1.5 SD  | 39 (97.5)              | 31 (77.5)              | 11.323 | .025   | [1.360, 94.248]         |
| 1ale sex   | 22 (55%   | %) 28 ( <sup>*</sup>                               | 70%)                   | 1.920                      | .166                       | < - 1.5 SD  | 1 (2.5)                | 9 (22.5)               |        |        |                         |
| isaasa duration months                             | 14 60 + 6 /                                       | , , ,<br>IE 1772+                                  | ,<br>7 )1              | 2 106                      | 060                        | TMT-B   |                        |                        |        |        |                         |
| isease duration, months                            | 14.00 ± 0.4                                       | +J 17.45 ±   | 7.21                   | 5.400                      | .009                       | > - 1.5 SD  | 39 (97.5)              | 35 (87.5)              | 5.571  | .125   | [.620, 50.031]          |
| PDRS III   | 15.02 ± 5.2                                       | 29 24.45 ±   | 6.46                   | 50.856                     | >.0001                     | < - 1.5 SD  | 1 (2.5)                | 5 (12.5)               |        |        |                         |
| Tremor score                                       | 2.18 ± 2  | .5 2.23 ±  | 2.78                   | .007                       | .933                       | Digit Span forward                                | 1                      |                        |        |        |                         |
| Rigidity score                                     | 2.78 ± 2.1  | 17 5.20 ±  | 3.37                   | 14.576                     | >.0001                     | > - 1.5 SD  | 39 (97.5)              | 39 (97.5)              | 1      | 1      | [.060, 16.562]          |
| Bradykinesia score                                 | 7.20 ± 3.5  | 53 12.28 ±   | 4.40                   | 32.288                     | >.0001                     | < - 1.5 SD  | 1 (2.5)                | 1 (2.5)                |        |        |                         |
| Gait/Postural stability score                      | .90 ± .92   | 28 2.62 ±  | 1.62                   | 33.889                     | >.0001                     | Memory  |                        |                        |        |        |                         |
| oworth Sleepiness Scale (ESS)                      | 3.68 ± 2.72                                       | 29 4.28 ± 3  | 8.731                  | .622                       | .433                       | > - 1.5 SD  | 36 (90)                | 20 (50)                | 9.000  | >.0001 | [2.698, 30.021]         |
| eck Depression Inventory (BDI)                     | 6.78 + 4.13                                       | 81 8.34 + 6  | 5.494                  | .940                       | .232                       | < - 1.5 SD  | 4 (10)                 | 20 (50)                |        |        |                         |
| de ef en est                                       | 0.70 2 1.10                                       |  | . 13 1                 | 1 251                      | 202                        | RAVLT-delaved red                                 | all                    |                        |        |        |                         |
| de of onset:                                       |   |  |                        | 1.251                      | .263                       | > - 1.5 SD  | 35 (87.5)              | 27 (67.5)              | 3.370  | .038   | [1.070, 10.613]         |
| Left   | 22 (55%   | %) 17 (42  | 2.5%)                  |                            |                            | < - 1.5 SD  | 5 (12.5)               | 13 (32.5)              |        |        |                         |
| Right  | 18 (45%   | %) 23 (57  | 7.5%)                  |                            |                            | ROCF-immediate                                    | recall                 |                        |        |        |                         |
| O subtype classification:                          |   |  |                        | 3.242                      | .198                       | > - 1.5 SD  | 19 (47.5)              | 15 (37.5)              | 1.508  | .367   | [.618, 3.678]           |
| Tremor-D   | 16 (409   | %) 10 (ž   | 25%)                   |                            |                            | < - 1.5 SD  | 21 (52.5)              | 25 (62.5)              |        |        |                         |
| PIGD-D   | 17 (42.59   | %) <u>25 (6</u> 2                                  | 2.5%)                  |                            |                            | Prose recall test                                 |                        |                        |        |        |                         |
| Not dotormined                                     | -/(-=,  | () <u> </u>  |                        |                            |                            | > - 1.5 SD  | 25 (62.5)              | 16 (40)                | 2.500  | .046   | [1.016, 6.149]          |
| Not determined                                     | 7 (17.5%  | %) 5(12  | 2.5%)                  |                            |                            | < - 1.5 SD  | 15 (37.5)              | 24 (60)                |        |        |                         |
| atter hyperintensity.                              |   |  |                        |                            |                            | > - 1.5 SD<br>< - 1.5 SD                          | 37 (92.5)<br>3 (7.5)   | 30 (75)<br>10 (25)     | 4.111  | .044   | [1.037, 16.295]         |
|  |   |  |                        |                            |                            | Catagony fluonay                                  |                        |                        |        |        |                         |
|  |   |  |                        |                            |                            | > - 1.5 SD  | .ask<br>38 (95)        | 30 (75)                | 6.333  | .023   | [1.289, 31.115]         |
| able 2. Cognitive performance                      | of the patients ir                                | n Hoehn & Y  | ahr sta                | ige I vs. s                | tage II                    | < - 1.5 SD  | 2 (5)                  | 10 (25)                |        |        |                         |
| roup; data are reported as mea                     | n standard devia                                  | ation.   |                        |                            |                            | MCST-nerseverati                                  | ve errors              |                        |        |        |                         |
|  | HY stage I  | HY stage II  | F                      | - F                        | ο η <sup>2</sup>           | > - 1.5 SD  | 31 (77.5)              | 29 (72.5)              | 1.307  | .606   | [.473, 3.609]           |
| Attention/Working memory                           | (N = 40)  | (N = 40)   |                        |                            |                            | < - 1.5 SD  | 9 (22.5)               | 11 (27.5)              |        |        |                         |
|  | /12 02+17 71                                      | 62 52+12 75  | 3 500                  | 0.65                       | 5 044                      | MCST-number of                                    | categories achiev      | ed                     | 1 507  | 2/11   | [615 4 066]             |
|  | 45.95±17.71                                       | 05.55±42.75  | 5.509                  | .005                       | .044                       | < - 1.5 SD  | 29 (72.5)<br>11 (27.5) | 25 (82.5)<br>15 (37.5) | 1.382  | .541   | [.015, 4.000]           |
| MT-B   | 122.13±57.6<br>5                                  | 163.62±96.1<br>1                                   | 2.416                  | 5 .12 <sup>4</sup>         | 4 .031                     |   |                        |                        |        |        |                         |
| Digit Span forward <sup>a</sup>                    | 5.48±1.08   | 5.13±1.04  | .658                   | .420                       | .009                       | 10 points CDT<br>> - 1.5 SD                       | 38 (95)                | 28 (70)                | 8,143  | .009   | [1.686, 39,317]         |
| /lemory<br>AVLT-immediate recall                   | 38.2±8.38   | 29.08±9.36   | 16.307                 | <b>&lt;.000</b> 1          | L .177                     | < - 1.5 SD  | 2 (5)                  | 12 (30)                | 01210  |        | [1.000, 00.017]         |
| AVLT-delayed recall <sup>a</sup>                   | 7.05±2.49   | 5.28±3.07  | 4.602                  | .035                       | 5 .057                     | Frontal Assessmen                                 | nt Battery (FAB)       |                        |        |        |                         |
| AVLT-recognition                                   | 13.07±2.56  | 12.2±2.88  | .953                   | .332                       | 2.012                      | > - 1.5 SD  | 37 (92.5)              | 26 (65)                | 6.641  | .006   | [1.732, 25.465]         |
| OCF-immediate recall                               | 9.58±6.26   | 7.49±6.21  | .762                   | .385                       | 5 .010                     | N - T'2 2N  | (۲.၁)                  | 14 (35)                |        |        |                         |
| rose recall test <sup>a</sup>                      |   |  | 7 0 2 7                | 010                        | 0.85                       | Visuospatial funct                                | ions                   |                        |        |        |                         |
| xecutive function                                  | 9.85±3.6  | 7.3±3.62   | 7.027                  | .010                       | .005                       | Visuospatiai rariet                               | 10115                  |                        |        |        |                         |
|  | 9.85±3.6<br>29.5±10.96                            | 7.3±3.62<br>23.88±10.96                            | 2.196                  | 5 .143                     | 3 .028                     | ROCF-copy<br>> - 1.5 SD                           | 28 (70)                | 12 (30)                | 5.444  | .001   | [2.092, 14.168]         |
| ategory fluency task                               | 9.85±3.6<br>29.5±10.96<br>36.23±6.85              | 7.3±3.62<br>23.88±10.96<br>31.85±8.10              | 2.196                  | 5 .143<br>5 .071           | 3 .028<br>L .042           | ROCF-copy<br>> - 1.5 SD<br>< - 1.5 SD             | 28 (70)<br>12 (30)     | 12 (30)<br>28 (70)     | 5.444  | .001   | [2.092, 14.168]         |
| Category fluency task<br>MCST-perseverative errors | 9.85±3.6<br>29.5±10.96<br>36.23±6.85<br>4.23±6.71 | 7.3±3.62<br>23.88±10.96<br>31.85±8.10<br>5.75±7.74 | 2.196<br>3.365<br>.039 | 5 .143<br>5 .071<br>9 .845 | 3 .028<br>L .042<br>5 .001 | ROCF-copy<br>> - 1.5 SD<br>< - 1.5 SD<br>Language | 28 (70)<br>12 (30)     | 12 (30)<br>28 (70)     | 5.444  | .001   | [2.092 <i>,</i> 14.168] |

**DISCUSSION AND CONCLUSIONS:** Our results demonstrate that at the time of first diagnosis, motor impairment of de novo PD patients is significantly associated with reduced performances on cognitive tests, particularly in memory, executive, and visuospatial domains. In addition, our study suggests that de novo PD patients at a HY stage II have a higher risk of cognitive impairment than the patients in HY stage I. Compared with those at HY stage I, patients at HY stage II had higher odds ratio of having attention, memory, visuospatial, and executive dysfunctions. Moreover, in the present study we did not find any significant differences between PIGD-dominant TD and group on neuropsychological tests. Taken together, our results suggest that the rate of motor impairment, closely related to prevalence of MCI, may contribute to identify those patients most likely to

|  | HY stage I<br>(N = 40) | HY stage II<br>(N = 40) | F      | р      | η²   |
|--|------------------------|-------------------------|--------|--------|------|
| Attention/Working memory                               |                        |                         |        |        |      |
| TMT-A <sup>a</sup>                                     | 43.93±17.71            | 63.53±42.75             | 3.509  | .065   | .044 |
| TMT-B  | 122.13±57.6<br>5       | 163.62±96.1<br>1        | 2.416  | .124   | .031 |
| Digit Span forward <sup>a</sup>                        | 5.48±1.08              | 5.13±1.04               | .658   | .420   | .009 |
| Memory<br>RAVLT-immediate recall                       | 38.2±8.38              | 29.08±9.36              | 16.307 | <.0001 | .177 |
| RAVLT-delayed recall <sup>a</sup>                      | 7.05±2.49              | 5.28±3.07               | 4.602  | .035   | .057 |
| RAVLT-recognition                                      | 13.07±2.56             | 12.2±2.88               | .953   | .332   | .012 |
| ROCF-immediate recall                                  | 9.58±6.26              | 7.49±6.21               | .762   | .385   | .010 |
| Prose recall test <sup>a</sup>                         | 9.85±3.6               | 7.3±3.62                | 7.027  | .010   | .085 |
| Executive function<br>Letter fluency task <sup>a</sup> | 29.5±10.96             | 23.88±10.96             | 2.196  | .143   | .028 |
| Category fluency task                                  | 36.23±6.85             | 31.85±8.10              | 3.365  | .071   | .042 |
| MCST-perseverative errors                              | 4.23±6.71              | 5.75±7.74               | .039   | .845   | .001 |
| MCST-number of categories achieved <sup>a</sup>        | 4.85±1.77              | 4.08±1.88               | 1.180  | .281   | .015 |
| 10 points CDT  | 8.23±1.33              | 6.60±2.36               | 9.558  | .002   | .112 |
| Frontal Assessment Battery (FAB)                       | 15.48±1.72             | 13.78±2.93              | 5.646  | .020   | .069 |
| Visuospatial function<br>ROCF-copy <sup>a</sup>        | 28.95±6.13             | 20.51±9.14              | 19.784 | <.0001 | .207 |
| Language<br>Boston Naming Test (BNT)                   | 45.92±4.92             | 42.09±6.66              | 5.498  | .022   | .067 |

Note. a, tests used for the diagnosis of Parkinson's Disease-Mild Cognitive Impairment according to the Movement Disorder Society Task Force Level I criteria; significant differences according to Bonferroni criterion (.05/16 = .003) are shown in bold;  $\eta^2$ , Eta-squared; TMT, Trail Making Test; RAVLT, Rey's Auditory Verbal Learning Test; MCST (Nelson's modification), Modified Card Sorting Test; CDT, Clock Drawing Test; ROCF, Rey-Osterrieth Complex Figure Test.

LOWLENDR, O'Eds Ratio; 30,7 Standard Deviation; TMT, Trail Making Test; RAVLT, Rey's Auditory Verbal Learning Test; MCST (Nelson's modification), Modified Card Sorting Test; CDT, Clock Drawing Test; ROCF, Rey-Osterrieth Complex Figure Test.

